Pharmaceutical Executive July 2017

July 2017 | Volume 37, Issue 7
Pharmaceutical Executive July 2017
From the Editor
As we step further into the waters of value-based contracting arrangements, lessons learned must be shared—including the role of the patient in the equation.
The industry’s potential in tapping digital health to transform patient care hinges on new shifts in culture and business strategy. Michelle Maskaly reports.
David Keane outlines four best practices in implementing AI-based technology to help achieve physician-engagement wins.
With healthcare professionals and patients now collecting much of their information online, there is new opportunity for “digital opinion influencers” to amplify traditional KOL messaging—or create their own.
More on Digital Health
Outlining the four core elements pharma companies need to lay the foundation for a solid digital health infrastructure.
Digital interventions in drug adherence regimes are evolving to new levels of sophistication, but patient-behavior and privacy issues still present significant challenges.
Q&A with Merck KGaA’s Simon Sturge spotlights the development of one injection device that is helping change the treatment-adherence landscape.
Highlighting a sampling of new digital health devices that span the wide focus terrain in health technology.
Excitement over more new treatments for cancer and rare diseases is offset by cringing over prices.
For better alignment of coverage and risk, evidence-based arguments are critical during the underwriting process, writes Daniel Brettler.
By Pharmaceutical Executive Editors
Three messages that resonated from this year’s annual meeting of the Drug Information Association.
As digital technologies transform drug development and marketing, a retooled medical affairs function can be a competitive differentiator.
The recent EFPIA and EU health council conferences highlight the growing divisions—and resentments—between industry and governments in Europe.
lorem ipsum